Literature DB >> 20682838

Kinase-mediated quasi-dimers of EGFR.

Erez M Bublil1, Gur Pines, Gargi Patel, Gilbert Fruhwirth, Tony Ng, Yosef Yarden.   

Abstract

Ligand-induced dimerization of the epidermal growth factor receptor (ErbB-1/EGFR) involves conformational changes that expose an extracellular dimerization interface. Subsequent alterations within the cytoplasmic kinase domain, which culminate in tyrosine phosphorylation, are less understood. Our study addressed this question by using two strategies: a chimeric receptor approach employed ErbB-3, whose defective kinase domain was replaced by the respective part of EGFR. The implanted full-length kinase, unlike its subdomains, conferred dimerization and catalysis. The data infer that the kinase function of EGFR is restrained by the carboxyl tail; once grafted distally to the ectopic tail of ErbB-3, the kinase domain acquires quasi-dimerization and activation. In an attempt to alternatively refold the cytoplasmic tail, our other approach employed kinase inhibitors. Biophysical measurements and covalent cross-linking analyses showed that inhibitors targeting the active conformation of EGFR, in contrast to a compound recognizing the inactive conformation, induce quasi-dimers in a manner similar to the chimeric ErbB-3 molecule. Collectively, these observations unveil kinase domain-mediated quasi-dimers, which are regulated by an autoinhibitory carboxyl tail. On the basis of these observations, we propose that quasi-dimers precede formation of ligand-induced, fully active dimers, which are stabilized by both extracellular and intracellular receptor-receptor interactions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20682838      PMCID: PMC2992368          DOI: 10.1096/fj.10-166199

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  42 in total

Review 1.  EGF mutant receptor vIII as a molecular target in cancer therapy.

Authors:  C T Kuan; C J Wikstrand; D D Bigner
Journal:  Endocr Relat Cancer       Date:  2001-06       Impact factor: 5.678

Review 2.  The EGF receptor family: spearheading a merger of signaling and therapeutics.

Authors:  Erez M Bublil; Yosef Yarden
Journal:  Curr Opin Cell Biol       Date:  2007-02-20       Impact factor: 8.382

Review 3.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

4.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Authors:  T Schindler; W Bornmann; P Pellicena; W T Miller; B Clarkson; J Kuriyan
Journal:  Science       Date:  2000-09-15       Impact factor: 47.728

5.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

Authors:  L Frederick; X Y Wang; G Eley; C D James
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

Review 6.  The ErbB kinase domain: structural perspectives into kinase activation and inhibition.

Authors:  Ron Bose; Xuewu Zhang
Journal:  Exp Cell Res       Date:  2008-08-15       Impact factor: 3.905

7.  Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling.

Authors:  Xiaochun Yu; Kailash D Sharma; Tsuyoshi Takahashi; Ryo Iwamoto; Eisuke Mekada
Journal:  Mol Biol Cell       Date:  2002-07       Impact factor: 4.138

Review 8.  Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors.

Authors:  Meytal Landau; Nir Ben-Tal
Journal:  Biochim Biophys Acta       Date:  2007-08-22

Review 9.  Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.

Authors:  Neil Spector
Journal:  Clin Breast Cancer       Date:  2008-03       Impact factor: 3.225

10.  Activated ezrin promotes cell migration through recruitment of the GEF Dbl to lipid rafts and preferential downstream activation of Cdc42.

Authors:  Soren Prag; Maddy Parsons; Melanie D Keppler; Simon M Ameer-Beg; Paul Barber; James Hunt; Andrew J Beavil; Rosy Calvert; Monique Arpin; Borivoj Vojnovic; Tony Ng
Journal:  Mol Biol Cell       Date:  2007-05-30       Impact factor: 4.138

View more
  27 in total

1.  The membrane-proximal intracellular domain of the epidermal growth factor receptor underlies negative cooperativity in ligand binding.

Authors:  Sangeeta Adak; Katherine S Yang; Jennifer Macdonald-Obermann; Linda J Pike
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

Review 2.  Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide-generating machinery and epidermal growth factor receptor.

Authors:  Tzipora Goldkorn; Simone Filosto; Samuel Chung
Journal:  Antioxid Redox Signal       Date:  2014-07-01       Impact factor: 8.401

3.  Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.

Authors:  Nadège Gaborit; Christel Larbouret; Julie Vallaghe; Frédéric Peyrusson; Caroline Bascoul-Mollevi; Evelyne Crapez; David Azria; Thierry Chardès; Marie-Alix Poul; Gérard Mathis; Hervé Bazin; André Pèlegrin
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

4.  erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.

Authors:  Mara P Steinkamp; Shalini T Low-Nam; Shujie Yang; Keith A Lidke; Diane S Lidke; Bridget S Wilson
Journal:  Mol Cell Biol       Date:  2013-12-30       Impact factor: 4.272

5.  Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.

Authors:  Jennifer L Macdonald-Obermann; Sangeeta Adak; Ralf Landgraf; David Piwnica-Worms; Linda J Pike
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

6.  Integrated analysis reveals that STAT3 is central to the crosstalk between HER/ErbB receptor signaling pathways in human mammary epithelial cells.

Authors:  Chunhong Gong; Yi Zhang; Harish Shankaran; Haluk Resat
Journal:  Mol Biosyst       Date:  2014-10-15

7.  Exploring higher-order EGFR oligomerisation and phosphorylation--a combined experimental and theoretical approach.

Authors:  Noga Kozer; Dipak Barua; Suzanne Orchard; Eduoard C Nice; Antony W Burgess; William S Hlavacek; Andrew H A Clayton
Journal:  Mol Biosyst       Date:  2013-04-30

8.  Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor.

Authors:  Erika Kovacs; Rahul Das; Qi Wang; Timothy S Collier; Aaron Cantor; Yongjian Huang; Kathryn Wong; Amar Mirza; Tiago Barros; Patricia Grob; Natalia Jura; Ron Bose; John Kuriyan
Journal:  Mol Cell Biol       Date:  2015-06-29       Impact factor: 4.272

9.  EGFR: tale of the C-terminal tail.

Authors:  Ketan S Gajiwala
Journal:  Protein Sci       Date:  2013-06-11       Impact factor: 6.725

Review 10.  Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

Authors:  Mariana Segovia-Mendoza; María E González-González; David Barrera; Lorenza Díaz; Rocío García-Becerra
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.